Takeda Pharmaceutical Company Limited Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019
Takeda Pharmaceutical Company Limited (TKPHF) had Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 of 4.14 thousand JPY/shares as of 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 · last filed 2025-06-25
- 2025-03-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 4.14K JPY/shares.
- 2024-03-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 4.14K JPY/shares.
- 2023-03-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 4.11K JPY/shares.
- 2022-03-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 4.09K JPY/shares.
| Period end | Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 |
|---|---|
| 2025-03-31 | 4.14K JPY/shares 20-F · filed 2025-06-25 |
| 2024-03-31 | 4.14K JPY/shares 20-F · filed 2025-06-25 |
| 2023-03-31 | 4.11K JPY/shares 20-F · filed 2025-06-25 |
| 2022-03-31 | 4.09K JPY/shares 20-F · filed 2025-06-25 |
| 2021-03-31 | 4.08K JPY/shares 20-F · filed 2024-06-26 |
| 2020-03-31 | 4.07K JPY/shares 20-F · filed 2023-06-28 |
| 2019-03-31 | 4.05K JPY/shares 20-F · filed 2022-06-29 |
| 2018-03-31 | 4.05K JPY/shares 20-F · filed 2021-06-29 |
| 2017-03-31 | 4.03K JPY/shares 20-F · filed 2020-06-24 |